Macitentan (Opsumit®)

Assessment Status Rapid Review Complete
Drug Macitentan
Brand Opsumit®
Indication Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.
Assessment Process
Rapid review commissioned 10/01/2014
Rapid review completed 27/01/2014
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended